Abstract
Background:Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with an inadequate response to conventional synthetic...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have